BO-110 Polycationic Complexes for Selective Cancer Cell Death
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for melanoma and other cancers face challenges such as low efficacy, severe toxicities, and resistance due to the ability of cancer cells to evade apoptosis and immune therapies, with existing compounds like pIC showing low stability and limited antitumoral effects, and the need for new therapeutic targets and agents that can selectively target tumor cells without affecting normal cells.
Innovation Solution
The development of a process to identify compounds that activate MDA-5 and induce autophagy and apoptosis in cancer cells, using a combination of double-stranded RNA (dsRNA) and a polycation like BO-110, which selectively kills tumor cells by promoting dual induction of autophagy and apoptosis, independent of p53 status and immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pIC is used as a therapeutic agent against melanoma, then immune system stimulation is achieved, but low stability and low induction of IFN result in absence of antitumoral effect
Solution Approach 1:
The patent uses polycations (such as PEI, poly-L-lysine, or chitosan) as intermediary carriers to deliver dsRNA or viral RNA to tumor cells. These polycationic complexes protect the RNA from degradation, enhance cellular uptake, and enable targeted delivery to cancer cells, thereby resolving the stability issue of naked pIC while maintaining immune stimulation capability
Solution Approach 2:
The invention creates composite therapeutic agents by combining dsRNA or viral RNA with polycations to form stable complexes. This composite structure provides both the immunostimulatory effect of RNA and the stability and targeting capability of polycations, resulting in effective antitumoral activity that neither component achieves alone
2Reliability
If standard chemotherapy is used to kill tumor cells, then cell death is achieved, but severe toxicities occur in normal cellular compartments
Solution Approach 1:
The patent employs polycationic complexes that exhibit selective toxicity toward tumor cells rather than normal cells. The complexes are designed to target cancer cells specifically, inducing cell death through mechanisms such as endosomal rupture and cytosolic RNA release, while sparing normal cellular compartments from damage
Solution Approach 2:
The therapeutic mechanism exploits the tumor cells' own vulnerabilities and metabolic characteristics. The polycationic RNA complexes trigger intrinsic cell death pathways and immune responses that are selectively activated in cancer cells, allowing the treatment to work through the target cells' own biological processes rather than imposing external damage
3Reliability
If immunotherapy is used to boost cytotoxic T cells and antigen presenting cells, then immune response is enhanced, but melanoma cells bypass therapy by downregulating immunoreactive surface markers
Solution Approach 1:
Instead of trying to enhance adaptive immunity through T cells and antibodies (conventional approach), the patent inverts the strategy by directly activating innate immune pathways through TLR3 and other pattern recognition receptors. This approach bypasses the need for antigen presentation and T cell recognition, targeting the tumor cells directly with immunostimulatory RNA that triggers innate immune-mediated cell death
Solution Approach 2:
The invention extracts and directly targets the core immunostimulatory function by delivering dsRNA or viral RNA that directly activates TLR3 and other innate immune receptors on tumor cells. This eliminates the need for complex antigen presentation pathways and T cell activation, directly engaging the immune system's first line of defense against the tumor
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 2
AI summary
Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-I. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine poly cation (PEI), for the manufacture of medicines for the treatment of cancer.